ImmVirX selected for Clinical E-Poster Presentation at ESMO Congress, Berlin
Melbourne, Australia 25 July 2025 – ImmVirX Pty Limited, a life sciences company focused on developing next-generation, receptor targeted oncolytic RNA immunotherapies to transform outcomes for patients with some of the most prevalent and challenging cancer types, will present an e-poster at the European Society for Medical Oncology (ESMO) Congress taking place in Berlin, Germany […]
